BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 8351927)

  • 1. [Reducing blood pressure and modification of coronary risk factors by therapy with doxazosin].
    Hitzenberger G; Ganzinger U
    Wien Klin Wochenschr; 1993; 105(13):371-6. PubMed ID: 8351927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism.
    Pessina AC; Ciccariello L; Perrone F; Stoico V; Gussoni G; Scotti A; Muggeo M
    Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):137-47. PubMed ID: 16487914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Doxazosin in the treatment of light-to-moderate arterial hypertension in a non-comparative multicenter study].
    Pessina AC
    Clin Ter; 1995 Jan; 146(1):3-12. PubMed ID: 7705011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Usefulness of the alpha1-blocker doxazosin as a third-line antihypertensive drug.
    Ohta Y; Tsuchihashi T; Onaka U; Eto K; Ueno M
    Hypertens Res; 2007 Apr; 30(4):301-6. PubMed ID: 17541208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective alpha 1 inhibition with doxazosin in hypertensive smokers and non-smokers: haemodynamic and metabolic effects.
    Westheim A; Daae LN; Kierulf P; Brusletto B; Holme I; Syvertsen JO
    J Hypertens Suppl; 1990 Sep; 8(5):S41-6. PubMed ID: 1981076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of doxazosin gastrointestinal therapeutic system on patients with uncontrolled hypertension: the ASOCIA Study.
    de Alvaro F; Hernández-Presa MA;
    J Cardiovasc Pharmacol; 2006 Feb; 47(2):271-6. PubMed ID: 16495766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
    Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
    Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy and tolerance of doxazosin in the treatment of isolated systolic hypertension in hypertensive patients over 60 years of age].
    Calvo C; López E; Barrio E; Espejo J; Ruiz M; Vega A
    An Med Interna; 1995 Mar; 12(3):122-6. PubMed ID: 7795118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Doxazosin in hypertension: results of a general practice study in 4809 patients.
    Langdon CG; Packard RS
    Br J Clin Pract; 1994; 48(6):293-8. PubMed ID: 7848789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 26-week, prospective, open-label, uncontrolled, multicenter study to evaluate the effect of an escalating-dose regimen of trandolapril on change in blood pressure in treatment-naive and concurrently treated adult hypertensive subjects (TRAIL).
    Tytus RH; Burgess ED; Assouline L; Vanjaka A
    Clin Ther; 2007 Feb; 29(2):305-15. PubMed ID: 17472822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of a phase III, 8-week, multicenter, prospective, randomized, double-blind, parallel-group clinical trial to assess the effects of amlodipine camsylate versus amlodipine besylate in Korean adults with mild to moderate hypertension.
    Kim SH; Kim YD; Lim DS; Yoon MH; Ahn YK; On YK; Lee JW; Kim IJ; Park JB; Kim JJ; Chung WS; Yang JY; Seo HS; Shin EK; Kim HS;
    Clin Ther; 2007 Sep; 29(9):1924-36. PubMed ID: 18035192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Doxazosin (alpha 1-adrenoreceptor antagonist) used in primary hypertension and it's beneficial effect on lipid metabolism].
    Sznajderman M; Chotkowska E; Peczkowska M; Sawicki M; Janaszek-Sitkowska H; Wiernikowska-Wegorek I; Galewicz A; Cybulska I
    Kardiol Pol; 1993 Feb; 38(2):107-11. PubMed ID: 8230980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of tamsulosin hydrochloride compared to doxazosin in the treatment of Indonesian patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
    Rahardjo D; Soebadi DM; Sugandi S; Birowo P; Djati W; Wahyudi I
    Int J Urol; 2006 Nov; 13(11):1405-9. PubMed ID: 17083392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Doxazosin for the treatment of arterial hypertension].
    Mozzato MG; Semplicini A; Serena L; Valle R; Casolino P; Buzzaccarini F; Rubino N; Giusto M; Pessina AC
    Cardiologia; 1990 Nov; 35(11):931-6. PubMed ID: 2151571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term follow-up study to evaluate the efficacy and safety of the doxazosin gastrointestinal therapeutic system in patients with benign prostatic hyperplasia with or without concomitant hypertension.
    Chung BH; Hong SJ
    BJU Int; 2006 Jan; 97(1):90-5. PubMed ID: 16336335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Doxazosin for benign prostatic hyperplasia: an open-label, baseline-controlled study in Korean general practice.
    Chung BH; Hong SJ; Lee MS
    Int J Urol; 2005 Feb; 12(2):159-65. PubMed ID: 15733110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Randomized, comparative study to evaluate efficacy and safety of doxazosin versus nitrendipine in the treatment of mild to moderate hypertension].
    Sanz Guajardo D; Espejo Martínez J
    An Med Interna; 1997 Jan; 14(1):15-9. PubMed ID: 9091027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Doxazosin GITS versus standard doxazosin in mild to moderate hypertension.
    Calvo C; Gil-Extremera B; Gomez-Fernández P; Masramon X; Pueyo C; Armada B
    Int J Cardiol; 2005 May; 101(1):97-104. PubMed ID: 15860390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Evaluation of the efficacy and tolerance of doxazosin vs. enalapril inaged patients with light to moderate arterial hypertension].
    Puddu P; Gallucci M; Curnis A; Pupita F; Ansuini R; Malacco E
    Clin Ter; 1995 Dec; 146(12):801-10. PubMed ID: 8681500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of essential arterial hypertension with hypercholesterolemia. Effects of an alpha-adrenergic blocker and an inhibitor of the angiotensin converting enzyme].
    Fernández Pinilla C; Luque Otero M; Martell Claros N; Alcázar de la Osa JM; Rodicio Díaz JL; Ruilope Urioste LM
    Med Clin (Barc); 1993 Jun; 101(5):168-71. PubMed ID: 8332009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.